To include your compound in the COVID-19 Resource Center, submit it here.

IPI-504: Preliminary Phase I data

Preliminary data from an open-label, dose-escalation Phase I trial showed that IPI-504

Read the full 122 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE